kabutan

HEALIOS Rebounds After Five-Day Losing Streak on Culture Supernatant Supply Agreement with South Korea's GeneCel◇

Wed Apr 8, 2026 9:19 am JST Catalyst

HEALIOS <4593> surged, rebounding after five consecutive days of losses. After the market close on the 7th, the company announced it had signed a supply agreement for culture supernatant ? a cosmetic raw material ? with GeneCel, a South Korean subsidiary of Alfresa Holdings <2784>, drawing buying interest on expectations of a positive earnings contribution.

Under the agreement, HEALIOS received an initial order worth \144 million for human (allogeneic) bone marrow-derived somatic stem cell culture supernatant (HLSI071). The company plans to begin shipping products sequentially from July, with revenue recognition expected from the third quarter of the fiscal year ending December 2026.

Note: The "◇" symbol in the title indicates that this article covers multiple stock issues.

Source: MINKABU PRESS

Related Articles